Avant Technologies Inc (AVAI)

$0.63 -0.01 (-1.81%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 173,900
Avg Vol 109,900
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 36%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Avant Technologies Inc. develops, acquires, and creates artificial intelligence (AI) technologies. The company publishes Thy News application for processing news from various sources. It also provides information technology (IT) consulting services, including project management and software administration, financial and asset management, service management, and event management. In addition, the company provides full-stack software development, database management, data integration, project mana...

Industry: Software - Application
Sector: Technology
Phone: 866 533 0065
Fax: 702 872 2060
Address:
5348 Vegas Drive, Las Vegas, United States
Awiz2
Awiz2 Jun. 5 at 3:19 PM
$AVAI VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham—where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's "most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB: AVAI), Butterfly Network, Inc. (NYSE: BFLY), AptarGroup, Inc. (NYSE: ATR), AstraZeneca PLC (NASDAQ: AZN), and Relay Therapeutics, Inc. (NASDAQ: RLAY).
0 · Reply
Awiz2
Awiz2 Jun. 5 at 3:15 PM
$AVAI VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB: AVAI), Medtronic plc (NYSE: MDT), Butterfly Network, Inc. (NYSE: BFLY), Oracle Corporation (NYSE: ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
0 · Reply
Awiz2
Awiz2 May. 30 at 12:49 PM
$AVAI Avant Technologies Analyst Ratings and Price Targets | OTC:AVAI | Benzinga Avant Technologies Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Avant Technologies Corp from these most-recent analyst ratings.
0 · Reply
Awiz2
Awiz2 May. 27 at 2:00 PM
$AVAI From streamlining diagnostics and automating clinical documentation to predicting disease and optimizing hospital operations, generative AI is now touching every layer of the care continuum. As policymakers in places like Connecticut debate how to regulate this growing influence, and initiatives like OpenAI's HealthBench push the frontier of model evaluation, a new class of enterprise-scale innovators is already moving ahead. Among them are several public companies straddling health tech, cloud AI, and data infrastructure — including Avant Technologies, Inc. (OTCQB: AVAI), Palantir Technologies Inc. (NASDAQ: PLTR), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Salesforce, Inc. (NYSE: CRM), and Alphabet Inc. (NASDAQ: GOOG, GOOGL).
0 · Reply
PenkeTrading
PenkeTrading May. 21 at 4:06 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Avant Technologies Inc.. Is that bullish or bearish? $AVAI #Avant #RsiOverbought #OTCQB
0 · Reply
Awiz2
Awiz2 May. 19 at 5:33 PM
$AVAI We should still be at $1.0 right now!
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 16 at 5:51 PM
Avant Technologies $AVAI moves to acquire Ainnova Tech ahead of key FDA meeting. Vision AI's 90% sensitivity in early detection and Latin America deployments show promise, but with $3K cash on hand, the clock is ticking. High-risk, high-reward play in the $110B healthcare AI race. https://www.prnewswire.com/news-releases/new-healthcare-ai-models-could-reshape-everything-from-burnout-to-diagnostics-302458034.html
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:52 PM
$AVAI Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s interactions with the FDA are paramount to marketing the technology portfolio in the United States. AVAI is an easy 10Xer from here actually 100Xer!!!!!
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:49 PM
$AVAI Palm Beach, FL – April 29, 2025 – According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in Diabetic Retinopathy Market is witnessing unprecedented growth, reshaping the landscape of diagnostic and therapeutic interventions for this prevalent and sight-threatening complication of diabetes. As technology continues to advance, artificial intelligence (AI) is emerging as a transformative force in healthcare, particularly in the domain of diabetic retinopathy (DR), where early detection and timely intervention are critical. The report said “AI applications in diabetic retinopathy are gaining momentum due to their ability to augment traditional diagnostic methods. Image analysis, a cornerstone in the detection of retinal abnormalities, has witnessed a paradigm shift with the incorporation of AI algorithms. These algorithms, trained on vast datas
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:48 PM
$AVAI April 29, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review. Ainnova is requesting a pre-submission meeting with the FDA's review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays
0 · Reply
Latest News on AVAI
No data available.
Awiz2
Awiz2 Jun. 5 at 3:19 PM
$AVAI VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham—where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's "most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB: AVAI), Butterfly Network, Inc. (NYSE: BFLY), AptarGroup, Inc. (NYSE: ATR), AstraZeneca PLC (NASDAQ: AZN), and Relay Therapeutics, Inc. (NASDAQ: RLAY).
0 · Reply
Awiz2
Awiz2 Jun. 5 at 3:15 PM
$AVAI VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB: AVAI), Medtronic plc (NYSE: MDT), Butterfly Network, Inc. (NYSE: BFLY), Oracle Corporation (NYSE: ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
0 · Reply
Awiz2
Awiz2 May. 30 at 12:49 PM
$AVAI Avant Technologies Analyst Ratings and Price Targets | OTC:AVAI | Benzinga Avant Technologies Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Avant Technologies Corp from these most-recent analyst ratings.
0 · Reply
Awiz2
Awiz2 May. 27 at 2:00 PM
$AVAI From streamlining diagnostics and automating clinical documentation to predicting disease and optimizing hospital operations, generative AI is now touching every layer of the care continuum. As policymakers in places like Connecticut debate how to regulate this growing influence, and initiatives like OpenAI's HealthBench push the frontier of model evaluation, a new class of enterprise-scale innovators is already moving ahead. Among them are several public companies straddling health tech, cloud AI, and data infrastructure — including Avant Technologies, Inc. (OTCQB: AVAI), Palantir Technologies Inc. (NASDAQ: PLTR), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Salesforce, Inc. (NYSE: CRM), and Alphabet Inc. (NASDAQ: GOOG, GOOGL).
0 · Reply
PenkeTrading
PenkeTrading May. 21 at 4:06 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Avant Technologies Inc.. Is that bullish or bearish? $AVAI #Avant #RsiOverbought #OTCQB
0 · Reply
Awiz2
Awiz2 May. 19 at 5:33 PM
$AVAI We should still be at $1.0 right now!
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 16 at 5:51 PM
Avant Technologies $AVAI moves to acquire Ainnova Tech ahead of key FDA meeting. Vision AI's 90% sensitivity in early detection and Latin America deployments show promise, but with $3K cash on hand, the clock is ticking. High-risk, high-reward play in the $110B healthcare AI race. https://www.prnewswire.com/news-releases/new-healthcare-ai-models-could-reshape-everything-from-burnout-to-diagnostics-302458034.html
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:52 PM
$AVAI Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s interactions with the FDA are paramount to marketing the technology portfolio in the United States. AVAI is an easy 10Xer from here actually 100Xer!!!!!
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:49 PM
$AVAI Palm Beach, FL – April 29, 2025 – According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in Diabetic Retinopathy Market is witnessing unprecedented growth, reshaping the landscape of diagnostic and therapeutic interventions for this prevalent and sight-threatening complication of diabetes. As technology continues to advance, artificial intelligence (AI) is emerging as a transformative force in healthcare, particularly in the domain of diabetic retinopathy (DR), where early detection and timely intervention are critical. The report said “AI applications in diabetic retinopathy are gaining momentum due to their ability to augment traditional diagnostic methods. Image analysis, a cornerstone in the detection of retinal abnormalities, has witnessed a paradigm shift with the incorporation of AI algorithms. These algorithms, trained on vast datas
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:48 PM
$AVAI April 29, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review. Ainnova is requesting a pre-submission meeting with the FDA's review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays
0 · Reply
Awiz2
Awiz2 Apr. 30 at 12:45 PM
$AVAI $1.00
0 · Reply
LewisDaKat
LewisDaKat Apr. 29 at 8:25 PM
News out $AVAI Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth https://marketwirenews.com/news-releases/global-artificial-intelligence-influence-on-diabetic-7317373099163747.html $AVAI
0 · Reply
jParkz
jParkz Apr. 29 at 8:00 PM
$AVAI News Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology https://marketwirenews.com/news-releases/avant-technologies-and-ainnova-request-pre-submissio-5903421478759933.html $AVAI
0 · Reply
Awiz2
Awiz2 Apr. 29 at 7:18 PM
$AVAI Looks like some new coming were getting ready to pop above $1.000
0 · Reply
WAYWARD_SUN
WAYWARD_SUN Apr. 29 at 1:14 AM
$AVAI
0 · Reply
Awiz2
Awiz2 Apr. 25 at 2:34 PM
$AVAI Turning positive on every time level!!! Just sayin!
0 · Reply
Awiz2
Awiz2 Apr. 24 at 11:57 AM
$AVAI This can grow 100X from here easy!!!!
0 · Reply
Awiz2
Awiz2 Apr. 24 at 11:56 AM
$AVAI The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.
0 · Reply
Awiz2
Awiz2 Apr. 24 at 11:55 AM
$AVAI At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.
0 · Reply
Awiz2
Awiz2 Apr. 24 at 11:53 AM
$AVAI Avant Technologies, Inc. (OTCQB: AVAI) and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit – Avant Technologies, Inc. (“Avant” or the “Company”) and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that following Ainnova’s sponsorship and its CEO’s key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova’s strong presence in Mexico by expanding its footprint across Latin America. Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care—from primary to highly specialized services. These pilot programs aim to demonstrate, (i) cost reduction in preventi
0 · Reply
LewisDaKat
LewisDaKat Apr. 16 at 4:25 PM
$AVAI News Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations https://marketwirenews.com/news-releases/global-ai-diagnostics-market-to-reach-8-54-billion-b-6884037890064975.html $AVAI
0 · Reply
jParkz
jParkz Apr. 16 at 4:00 PM
$AVAI News Article Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit https://marketwirenews.com/news-releases/avant-technologies-and-jv-partner-ainnova-accelerate-6420735702612531.html $AVAI
0 · Reply